文献速递细菌感染、耐药与抗菌药物

抗肠球菌经验性治疗对肠球菌血流感染生存的影响

What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections?
PubMed 文献 · Clin Infect Dis · 2026-01-01

一项回顾性多中心研究纳入2011-2019年758例单微生物肠球菌血流感染住院患者,其中342例接受体外有活性的经验性抗肠球菌治疗(EET)。经IPTW调整后,EET与14天和30天全因死亡率降低无显著相关;仅万古霉素耐药肠球菌血流感染亚组中EET降低14天死亡率。

要点

  • 在758例肠球菌血流感染患者中,342例接受EET,14天和30天死亡率分别为24%和42%。
  • 经IPTW调整后,EET并非14天和30天死亡率的独立预测因素,无显著死亡风险降低。
  • 亚组分析中,EET仅在万古霉素耐药肠球菌血流感染患者中降低14天死亡率。

核心结论

  • 早期给予EET可能对肠球菌血流感染患者的预后无影响。
  • EET可能仅对万古霉素耐药肠球菌血流感染患者的短期生存有影响。

研究设计与样本

  • 回顾性多中心研究,纳入2011-2019年所有住院的单微生物肠球菌血流感染患者,共758例(男性62%,中位年龄71岁)。
  • 暴露变量为EET,定义为从索引血培养采集后≤48小时内给予体外对分离肠球菌有活性的抗生素。
  • 主要结局为索引血培养后14天和30天全因死亡率,采用Kaplan-Meier曲线和IPTW调整后的多变量Cox回归评估EET对死亡率的影响。

主要发现

  • 342例患者接受EET;总体14天死亡率为24%,30天死亡率为42%。
  • 经IPTW调整后,合并症数量更多和无明确感染源的肠球菌血流感染是14天和30天死亡率的独立预测因素,而EET不是。
  • 在实际分析和IPTW调整分析中,EET均未与显著的死亡风险降低相关。
  • 亚组分析中,EET仅在万古霉素耐药肠球菌血流感染患者中降低14天死亡率。
  • 即使在237例(31%)从肠球菌血流感染发病到接受EET<24小时的患者中,EET也未影响生存。

临床怎么用

  • 对于肠球菌血流感染患者,早期给予EET可能不影响预后。
  • 对于万古霉素耐药肠球菌血流感染患者,EET可能影响短期生存。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of early administration of active anti-enterococcal empirical therapy (EET) on outcomes of patients with enterococcal bloodstream infections (EBSIs) is unclear. We compared the outcome of patients with EBSIs receiving or not empirical therapy targeting Enterococcus spp. METHODS: A retrospective multicenter study enrolling all hospitalized patients with monomicrobial EBSIs during 2011-2019. The exposure variable was considered receiving EET defined as administration of antibiotic(s) active in vitro against Enterococcus spp isolated from index blood cultures (BCs) ≤48 hours from collection. The primary outcome was 14- and 30-day all-cause mortality from index BC. The impact of EET on mortality was assessed by Kaplan-Meier curves and multivariable Cox regression after adjustment with inverse probability treatment weighting (IPTW). Post hoc analysis explored the effect of EET given ≤24 hours from EBSI onset. RESULTS: Overall, 758 patients (male, 62%; median age, 71 years) had EBSIs and 342 received EET; 14- and 30-day mortality was 24% and 42%, respectively. After IPTW adjustment, a higher number of comorbidities and EBSIs without an identified source but not EET were independent predictors of 14- and 30-day mortality. No significant mortality risk reduction was associated with EET in the real or the IPTW-adjusted analysis. In the subgroup analysis, EET reduced 14-day mortality only in patients with vancomycin-resistant EBSIs. Even among 237 (31%) patients receiving EET <24 hours from EBSI onset, EET did not affect survival. CONCLUSIONS: Early administration of EET may not have a prognostic impact in patients with EBSIs. Delivering EET might affect short-term survival only in patients with vancomycin-resistant EBSIs.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Bussini L, Bavaro DF, Brunetta E, et al. What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections? Clin Infect Dis. 2026. PMID: 40577528. doi:10.1093/cid/ciaf323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。